HUP0301231A2 - Protease inhibitors, pharmaceutical compositions containing them and their use - Google Patents
Protease inhibitors, pharmaceutical compositions containing them and their useInfo
- Publication number
- HUP0301231A2 HUP0301231A2 HU0301231A HUP0301231A HUP0301231A2 HU P0301231 A2 HUP0301231 A2 HU P0301231A2 HU 0301231 A HU0301231 A HU 0301231A HU P0301231 A HUP0301231 A HU P0301231A HU P0301231 A2 HUP0301231 A2 HU P0301231A2
- Authority
- HU
- Hungary
- Prior art keywords
- alkyl
- group
- het
- general formula
- hydrogen atom
- Prior art date
Links
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 title 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 10
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 4
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 1
- 102000005927 Cysteine Proteases Human genes 0.000 abstract 1
- 108010005843 Cysteine Proteases Proteins 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 206010003246 arthritis Diseases 0.000 abstract 1
- 210000000988 bone and bone Anatomy 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 210000000845 cartilage Anatomy 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 201000001245 periodontitis Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/08—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis for Pneumocystis carinii
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
- A61P33/12—Schistosomicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D223/06—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D223/12—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Epoxy Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
A találmány (IA) általános képletű vegyületekre - amelyek képletébenR1 jelentése általános képletű csoport; R2 jelentése 1-6 szénatomosalkilcsoport, Ar-(0-6 szénatomos alkil)- csoport, Het-(0-6 szénatomosalkil)-csoport, R9C(O)-, R9SO2-, R9R11NC(O)- vagy R9SO2R11NC(O)-általános képletű csoport; R3 jelentése 1-6 szénatomos alkilcsoport;R4 jelentése R5C(O)- általános képletű csoport; R5 jelentése Het-(0-6szénatomos alkil)-csoport; R9 jelentése 1-6 szénatomos alkilcsoport,(3-6 szénatomos cikloalkil)-(0-6 szénatomos alkil)-csoport, Ar-(0-6szénatomos alkil)-csoport és Het-(0-6 szénatomos alkil)-csoport; R11jelentése hidrogénatom, 1-6 szénatomos alkilcsoport, Ar -(0-6szénatomos alkil)-csoport és Het-(0-6 szénatomos alkil)-csoport; R'jelentése hidrogénatom; R< jelentése hidrogénatom; R<' jelentésehidrogénatom; R<< jelentése 1-6 szénatomos alkilcsoport, (3-6szénatomos cikloalkil)-(0-6 szénatomos alkil)-csoport, 2-6 szénatomosalkenilcsoport, 2-6 szénatomos alkinilcsoport, Ar-(0-6 szénatomosalkil)-csoport és Het-(0-6 szénatomos alkil)- csoport; és n értéke 1,2, 3, 4 vagy 5 valamint gyógyászatilag elfogadható sóik, hidrátjaik ésszolvátjaikra vonatkozik. A találmány magában foglalja a hatóanyagként(I) általános képletű vegyületeket tartalmazó gyógyszerkészítményeketés a vegyületek gyógyászati alkalmazását is. A találmány szerintivegyületek és gyógyszerkészítmények különösen jól alkalmazhatók azolyan betegségek kezelésére, amelyekben jelentős szerepet játszanakcisztein proteázok, különösen az excesszív csont- és porcvesztésesbetegségek, például az osteoporosis, a periodontitis és az arthritiskezelésére. ÓFor the compounds of the general formula (IA) of the invention - in the formula of which R1 means a group of the general formula; R2 is a C1-C6 alkyl group, Ar-(C0-6 alkyl) group, Het-(C0-6 alkyl) group, R9C(O)-, R9SO2-, R9R11NC(O)- or R9SO2R11NC(O)- group of general formula; R3 is an alkyl group having 1 to 6 carbon atoms; R4 is a group with the general formula R5C(O); R5 is Het-(C0-C6 alkyl); R9 is C1-6 alkyl, (C3-6 cycloalkyl)-(C0-6 alkyl), Ar-(C0-6 alkyl) and Het-(C0-6 alkyl); R11 means a hydrogen atom, a C1-6 alkyl group, an Ar -(C0-6 alkyl) group and a Het-(C0-6 alkyl) group; R' is a hydrogen atom; R< is a hydrogen atom; R<' is a hydrogen atom; R<< is a C1-6 alkyl group, (C3-6 cycloalkyl)-(C0-6 alkyl) group, C2-6 alkenyl group, C2-6 alkynyl group, Ar-(C0-6 alkyl) group and Het -(C0-C6 alkyl)- group; and the value of n is 1,2, 3, 4 or 5 and their pharmaceutically acceptable salts, hydrates and solvates. The invention also includes pharmaceutical preparations containing compounds of general formula (I) as active ingredients and the medicinal use of the compounds. The compounds and pharmaceutical preparations according to the invention are particularly well suited for the treatment of diseases in which cysteine proteases play a significant role, especially for the treatment of excessive bone and cartilage loss diseases such as osteoporosis, periodontitis and arthritis. HE
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US59384500A | 2000-06-14 | 2000-06-14 | |
| PCT/US2001/019062 WO2001095911A1 (en) | 2000-06-14 | 2001-06-14 | Protease inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUP0301231A2 true HUP0301231A2 (en) | 2003-08-28 |
Family
ID=24376433
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0301231A HUP0301231A2 (en) | 2000-06-14 | 2001-06-14 | Protease inhibitors, pharmaceutical compositions containing them and their use |
Country Status (25)
| Country | Link |
|---|---|
| EP (1) | EP1307204A4 (en) |
| JP (1) | JP2004503502A (en) |
| KR (1) | KR20030008220A (en) |
| CN (1) | CN1444481A (en) |
| AP (1) | AP2002002671A0 (en) |
| AR (1) | AR032622A1 (en) |
| AU (1) | AU2001268407A1 (en) |
| BG (1) | BG107327A (en) |
| BR (1) | BR0111693A (en) |
| CA (1) | CA2412353A1 (en) |
| CZ (1) | CZ20024086A3 (en) |
| EA (1) | EA200300018A1 (en) |
| EC (1) | ECSP024388A (en) |
| HU (1) | HUP0301231A2 (en) |
| IL (1) | IL153421A0 (en) |
| MA (1) | MA25758A1 (en) |
| MX (1) | MXPA02012442A (en) |
| NO (1) | NO20025786L (en) |
| NZ (1) | NZ522965A (en) |
| OA (1) | OA12288A (en) |
| PE (1) | PE20011374A1 (en) |
| PL (1) | PL360508A1 (en) |
| SK (1) | SK17592002A3 (en) |
| WO (1) | WO2001095911A1 (en) |
| ZA (1) | ZA200209808B (en) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001034159A1 (en) * | 1999-11-10 | 2001-05-17 | Smithkline Beecham Corporation | Protease inhibitors |
| JP2003513926A (en) * | 1999-11-10 | 2003-04-15 | スミスクライン・ビーチャム・コーポレイション | Protease inhibitor |
| EP1392657A4 (en) * | 2000-11-22 | 2004-03-10 | Smithkline Beecham Corp | Protease inhibitors |
| MXPA03007441A (en) | 2001-02-20 | 2004-10-15 | Chugai Pharmaceutical Co Ltd | Azoles as malonyl-coa decarboxylase inhibitors useful as metabolic modulators. |
| US7709510B2 (en) | 2001-02-20 | 2010-05-04 | Chugai Seiyaku Kabushiki Kaisha | Azoles as malonyl-CoA decarboxylase inhibitors useful as metabolic modulators |
| JP2004527575A (en) * | 2001-05-17 | 2004-09-09 | スミスクライン・ビーチャム・コーポレイション | Protease inhibitor |
| DE602004014937D1 (en) | 2003-08-01 | 2008-08-21 | Chugai Pharmaceutical Co Ltd | PIPERIDINE COMPOUNDS AS MALONYL-COA DECARBOXYLASE HEMMER |
| EP1653944B1 (en) | 2003-08-01 | 2010-11-10 | Chugai Seiyaku Kabushiki Kaisha | Heterocyclic compounds useful as malonyl-coa decarboxylase inhibitors |
| JP4773960B2 (en) | 2003-08-01 | 2011-09-14 | 中外製薬株式会社 | Cyanoguanidine-type azole compounds useful as malonyl-CoA decarboxylase inhibitors |
| JP5587790B2 (en) | 2008-01-09 | 2014-09-10 | アミュラ セラピューティクス リミティド | Compound |
| CN103275070A (en) * | 2013-05-10 | 2013-09-04 | 郑彪 | Tetracyclic compound for adjusting proliferation of mononuclear cells and application of tetracyclic compound |
| US9427441B2 (en) | 2014-02-19 | 2016-08-30 | Indiana University Research And Technology Corporation | Targeting primary cilia to treat glaucoma |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DZ2285A1 (en) * | 1996-08-08 | 2002-12-25 | Smithkline Beecham Corp | Cysteine protease inhibitors. |
| HUP0104768A3 (en) * | 1998-12-23 | 2002-05-28 | Smithkline Beecham Corp | 4-amino-3-oxo-azepanes as protease inhibitors and pharmaceutical compositions containing the same |
| WO2001034565A2 (en) * | 1999-11-10 | 2001-05-17 | Smithkline Beecham Corporation | Protease inhibitors |
| JP2003513926A (en) * | 1999-11-10 | 2003-04-15 | スミスクライン・ビーチャム・コーポレイション | Protease inhibitor |
| EP1320370A4 (en) * | 2000-09-01 | 2008-10-22 | Smithkline Beecham Corp | Method of treatment |
| EP1392657A4 (en) * | 2000-11-22 | 2004-03-10 | Smithkline Beecham Corp | Protease inhibitors |
| JP2004527575A (en) * | 2001-05-17 | 2004-09-09 | スミスクライン・ビーチャム・コーポレイション | Protease inhibitor |
-
2001
- 2001-06-14 NZ NZ522965A patent/NZ522965A/en unknown
- 2001-06-14 BR BR0111693-2A patent/BR0111693A/en not_active IP Right Cessation
- 2001-06-14 EA EA200300018A patent/EA200300018A1/en unknown
- 2001-06-14 KR KR1020027017045A patent/KR20030008220A/en not_active Application Discontinuation
- 2001-06-14 CA CA002412353A patent/CA2412353A1/en not_active Abandoned
- 2001-06-14 SK SK1759-2002A patent/SK17592002A3/en not_active Application Discontinuation
- 2001-06-14 HU HU0301231A patent/HUP0301231A2/en unknown
- 2001-06-14 JP JP2002510089A patent/JP2004503502A/en active Pending
- 2001-06-14 WO PCT/US2001/019062 patent/WO2001095911A1/en active IP Right Grant
- 2001-06-14 PE PE2001000566A patent/PE20011374A1/en not_active Application Discontinuation
- 2001-06-14 MX MXPA02012442A patent/MXPA02012442A/en unknown
- 2001-06-14 CZ CZ20024086A patent/CZ20024086A3/en unknown
- 2001-06-14 OA OA1200200377A patent/OA12288A/en unknown
- 2001-06-14 AU AU2001268407A patent/AU2001268407A1/en not_active Abandoned
- 2001-06-14 IL IL15342101A patent/IL153421A0/en unknown
- 2001-06-14 AR ARP010102840A patent/AR032622A1/en not_active Application Discontinuation
- 2001-06-14 CN CN01813500A patent/CN1444481A/en active Pending
- 2001-06-14 PL PL36050801A patent/PL360508A1/en not_active Application Discontinuation
- 2001-06-14 AP APAP/P/2002/002671A patent/AP2002002671A0/en unknown
- 2001-06-14 EP EP01946344A patent/EP1307204A4/en not_active Withdrawn
-
2002
- 2002-11-28 BG BG107327A patent/BG107327A/en unknown
- 2002-12-02 NO NO20025786A patent/NO20025786L/en not_active Application Discontinuation
- 2002-12-03 ZA ZA200209808A patent/ZA200209808B/en unknown
- 2002-12-12 EC EC2002004388A patent/ECSP024388A/en unknown
- 2002-12-13 MA MA26952A patent/MA25758A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PL360508A1 (en) | 2004-09-06 |
| MA25758A1 (en) | 2003-04-01 |
| WO2001095911A1 (en) | 2001-12-20 |
| MXPA02012442A (en) | 2003-04-25 |
| PE20011374A1 (en) | 2002-04-07 |
| ZA200209808B (en) | 2004-07-09 |
| SK17592002A3 (en) | 2003-05-02 |
| BR0111693A (en) | 2004-04-06 |
| AR032622A1 (en) | 2003-11-19 |
| KR20030008220A (en) | 2003-01-24 |
| CA2412353A1 (en) | 2001-12-20 |
| EP1307204A4 (en) | 2004-06-02 |
| NO20025786D0 (en) | 2002-12-02 |
| AP2002002671A0 (en) | 2002-12-31 |
| EA200300018A1 (en) | 2003-06-26 |
| CZ20024086A3 (en) | 2003-05-14 |
| IL153421A0 (en) | 2003-07-06 |
| NO20025786L (en) | 2003-02-12 |
| EP1307204A1 (en) | 2003-05-07 |
| ECSP024388A (en) | 2003-02-06 |
| CN1444481A (en) | 2003-09-24 |
| JP2004503502A (en) | 2004-02-05 |
| BG107327A (en) | 2003-07-31 |
| OA12288A (en) | 2003-12-12 |
| AU2001268407A1 (en) | 2001-12-24 |
| NZ522965A (en) | 2004-06-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP0104768A2 (en) | 4-amino-3-oxo-azepanes as protease inhibitors and pharmaceutical compositions containing the same | |
| MXPA02012033A (en) | 2-aminocarbonyl-9h-purine derivatives. | |
| HUP0303084A2 (en) | 17 beta-carbothioate 17-alpha-arylcarbonyloxyloxy androstane derivative as anti-inflammatory agents, process for their preparation and pharmaceutical compositions containing them | |
| YU82202A (en) | Tropane derivatives useful in therapy | |
| HUP0301231A2 (en) | Protease inhibitors, pharmaceutical compositions containing them and their use | |
| HUP0302487A2 (en) | New mandelic acid derivatives and their use as throbin inhibitors, process for their preparation and pharmaceutical compositions containing them | |
| HUP0102160A2 (en) | Use of alpha-keto enamine derivatives as ingredients | |
| TNSN03110A1 (en) | Azaindoles. | |
| HUP0301660A2 (en) | Use of neutral endopeptidase inhibitors (nepi) for the treatment of male sexual dysfunction and pharmaceutical compositions comprising thereof | |
| HUP0300434A2 (en) | Oxazole derivatives and their uses as tyrosine kinase inhibitors, process for their preparation and pharmaceutical compositions containing them | |
| HK1062677A1 (en) | 17Beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases | |
| HUP0300068A2 (en) | Protease inhibitors, their preparation, their use and pharmaceutical compositions containing them | |
| AP2001002204A0 (en) | Pyrazole derivatives. | |
| HUP0401235A2 (en) | Arylsulfonyl derivatives with 5-ht6 receptor affinity, process for producing them and pharmaceutical compositions containing them | |
| MXPA05012247A (en) | New benzimidazole derivatives. | |
| HUP0100865A2 (en) | Meta-azacyclic amino benzoic acid compounds and derivatives thereof being integrin antagonists, pharmaceutical compositions comprising thereof and their use | |
| HUP0002951A2 (en) | Bis-aminomethylcarbonyl compounds as protease inhibitors and pharmaceutical compositions containing them | |
| MXPA03000547A (en) | Use of derivatives of valproic acid and 2-valproenic acid amides for the treatment of mania in bipolar disorder. | |
| MY136859A (en) | Pyrrolidine derivatives as factor xa inhibitors | |
| HUP0003577A2 (en) | Tetrahydro gamma-carbolines, process for their preparation, their use and pharmaceutical compositions containing them | |
| HUP0402515A2 (en) | Novel substituted n-[4-(1h-imidazol-1-yl)-2-fluorophenyl]-3-(trifluoromethyl)-1h-pyrazole-5-carboxamides as inhibitors of factor xa, their use and pharmaceutical compositions containing them | |
| HUP0402033A2 (en) | Use of 2-amino-4-pyridylmethyl-thiazoline derivatives as inhibitors of inducible no-synthase, process for their preparation and pharmaceutical compositions containing them | |
| HUP0303195A2 (en) | O-substituted 6-methyl-tramadol derivatives, process for their preparation and pharmaceutical compositions containing them | |
| AP1396A (en) | 1-Trifluoromethyl-4-hydroxy-7-piperidinylaminomethylchroman derivatives. | |
| BRPI0416703A (en) | 3-hydroxy-4-pyridinones cycloalkyl derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD9A | Lapse of provisional protection due to non-payment of fees |